BioCentury | Jun 22, 2020
Emerging Company Profile

Prosit Sole: chimeric proteins for rare disease

...are in Phase III trials in the setting: an extended release formulation of nitazoxanide from Romark Laboratories L.C....
BioCentury | Dec 19, 2019

Benzoxaborole-based CPSF3 inhibitor to treat infections

...immunocompromised adult mouse models of infection. Next steps include testing AN3661 in larger animal models. Romark Laboratories L.C....
...pyruvate ferredoxin oxidoreductase inhibitor, to treat diarrhea caused by C. parvum and Giardia lamblia . Romark...
BioCentury | Dec 5, 2017
Distillery Therapeutics

Cancer

...models of colorectal cancer. Romark Laboratories L.C. markets Alinia, a pyruvate ferredoxin oxidoreductase inhibitor, to treat diarrhea. Romark...
BioCentury | Apr 29, 2013
Clinical News

NT-300: Phase III started

...Basel, Switzerland) markets Tamiflu under a license from Gilead Sciences Inc. (NASDAQ:GILD, Foster City, Calif.). Romark Laboratories L.C....
BioCentury | Aug 25, 2011
Targets & Mechanisms

More than one way to stop HCV

...a Phase I trial. BIntercell is testing its vaccine with the small molecule nitazoxanide from Romark Laboratories L.C....
BioCentury | Nov 15, 2010
Clinical News

Alinia nitazoxanide: Pilot trial data

...develop and commercialize Alinia in Japan under a 2009 deal (see BioCentury, Feb. 23, 2009). Romark Laboratories L.C....
BioCentury | Nov 1, 2010
Clinical News

Hepatitis C vaccine: Phase II start

...Next half, Intercell and Romark Laboratories L.C. (Tampa, Fla.) will begin a European Phase II trial in about...
...Phase II trial in about 60 treatment-naïve patients to compare Intercell's IC41 in combination with Romark's...
BioCentury | Nov 1, 2010
Clinical News

Alinia nitazoxanide: Phase II start

...Next half, Intercell AG (VSE:ICLL; OTCQX:INRLY, Vienna, Austria) and Romark will begin a European Phase II...
...Phase II trial in about 60 treatment-naïve patients to compare Intercell's IC41 in combination with Romark's...
...Japan under a 2009 deal (see BioCentury, Feb. 23, 2009). Roche markets Pegasys and Copegus. Romark Laboratories L.C....
BioCentury | May 3, 2010
Clinical News

Alinia nitazoxanide: Phase II data

...to treat diarrhea caused by Giardia lamblia or Cryptosporidium parvum. Roche markets Pegasys and Copegus. Romark Laboratories L.C....
BioCentury | Feb 8, 2010
Clinical News

Alinia nitazoxanide: Phase II started

...already marketed in the U.S. to treat diarrhea caused by Giardia lamblia or Cryptosporidium parvum. Romark Laboratories L.C....
Items per page:
1 - 10 of 41
BioCentury | Jun 22, 2020
Emerging Company Profile

Prosit Sole: chimeric proteins for rare disease

...are in Phase III trials in the setting: an extended release formulation of nitazoxanide from Romark Laboratories L.C....
BioCentury | Dec 19, 2019

Benzoxaborole-based CPSF3 inhibitor to treat infections

...immunocompromised adult mouse models of infection. Next steps include testing AN3661 in larger animal models. Romark Laboratories L.C....
...pyruvate ferredoxin oxidoreductase inhibitor, to treat diarrhea caused by C. parvum and Giardia lamblia . Romark...
BioCentury | Dec 5, 2017
Distillery Therapeutics

Cancer

...models of colorectal cancer. Romark Laboratories L.C. markets Alinia, a pyruvate ferredoxin oxidoreductase inhibitor, to treat diarrhea. Romark...
BioCentury | Apr 29, 2013
Clinical News

NT-300: Phase III started

...Basel, Switzerland) markets Tamiflu under a license from Gilead Sciences Inc. (NASDAQ:GILD, Foster City, Calif.). Romark Laboratories L.C....
BioCentury | Aug 25, 2011
Targets & Mechanisms

More than one way to stop HCV

...a Phase I trial. BIntercell is testing its vaccine with the small molecule nitazoxanide from Romark Laboratories L.C....
BioCentury | Nov 15, 2010
Clinical News

Alinia nitazoxanide: Pilot trial data

...develop and commercialize Alinia in Japan under a 2009 deal (see BioCentury, Feb. 23, 2009). Romark Laboratories L.C....
BioCentury | Nov 1, 2010
Clinical News

Hepatitis C vaccine: Phase II start

...Next half, Intercell and Romark Laboratories L.C. (Tampa, Fla.) will begin a European Phase II trial in about...
...Phase II trial in about 60 treatment-naïve patients to compare Intercell's IC41 in combination with Romark's...
BioCentury | Nov 1, 2010
Clinical News

Alinia nitazoxanide: Phase II start

...Next half, Intercell AG (VSE:ICLL; OTCQX:INRLY, Vienna, Austria) and Romark will begin a European Phase II...
...Phase II trial in about 60 treatment-naïve patients to compare Intercell's IC41 in combination with Romark's...
...Japan under a 2009 deal (see BioCentury, Feb. 23, 2009). Roche markets Pegasys and Copegus. Romark Laboratories L.C....
BioCentury | May 3, 2010
Clinical News

Alinia nitazoxanide: Phase II data

...to treat diarrhea caused by Giardia lamblia or Cryptosporidium parvum. Roche markets Pegasys and Copegus. Romark Laboratories L.C....
BioCentury | Feb 8, 2010
Clinical News

Alinia nitazoxanide: Phase II started

...already marketed in the U.S. to treat diarrhea caused by Giardia lamblia or Cryptosporidium parvum. Romark Laboratories L.C....
Items per page:
1 - 10 of 41